Venous and arterial ulcers look superficially similar but require opposite treatments. Learn the bedside differential, the ABI thresholds that drive decisions, and the evidence-based treatment pathways for each.
Healix360 supports access to advanced mobile wound care services. Care is coordinated and provided directly by licensed physicians and nurse practitioners experienced in the evaluation and management of chronic and complex wounds, including venous leg ulcers, arterial ulcers, mixed-etiology ulcers, and atypical lower-extremity wounds. We deliver coordinated care across nine Southern California counties (Los Angeles, Orange, Riverside, San Bernardino, Ventura, Santa Barbara, Kern, San Luis Obispo, and San Diego) and the Las Vegas metro area in Clark and Nye counties, Nevada. To request bedside differential evaluation of a non-healing leg ulcer, call 877-545-1300.
Venous and arterial ulcers are the two most common categories of chronic lower-extremity wounds, but their pathophysiology, presentation, and treatment are nearly opposite. A venous leg ulcer (VLU) is defined as an ulcer occurring in the lower leg, typically in the gaiter region between the malleolus and the mid-calf, caused by sustained ambulatory venous hypertension from valvular incompetence, deep venous obstruction, or calf-pump failure. An arterial ulcer is defined as an ulcer caused by inadequate arterial perfusion, typically in the distal foot, toes, or pretibial region, in the setting of peripheral arterial disease (PAD). The single most consequential clinical decision in lower-extremity wound care is establishing which etiology predominates, because compression—the cornerstone of venous treatment—can cause limb-threatening ischemia in patients with significant arterial disease.
Roughly 1% of the adult population in the United States carries a venous leg ulcer at any given time, accounting for an estimated 70% to 90% of all chronic leg wounds. Arterial ulcers represent 10% to 25% of leg ulcers, and mixed-etiology wounds—those with both venous insufficiency and significant arterial disease—account for an additional 10% to 20%. The Society for Vascular Surgery and the Wound Healing Society both emphasize that no leg ulcer should be treated empirically with compression until arterial inflow has been documented. Despite this, AHRQ data suggest that as many as one-third of community-treated leg ulcers receive compression without prior vascular assessment, exposing patients with undiagnosed PAD to preventable harm.
A focused bedside examination can correctly classify the majority of leg ulcers in less than five minutes. The clinician inspects ulcer location and morphology, palpates pulses, assesses surrounding skin, and documents associated findings. The ankle-brachial index, performed with a handheld Doppler and blood pressure cuff, then confirms the clinical impression. This examination should be standard on every initial leg-ulcer evaluation, and Healix360-coordinated clinicians complete and document it on the first visit.
ABI 0.9-1.3: normal arterial flow; venous treatment with full compression is safe. ABI 0.7-0.9: mild PAD; modified (reduced) compression is acceptable in many patients. ABI 0.5-0.7: moderate PAD; vascular consultation required before any compression. ABI under 0.5 or non-compressible vessels (ABI above 1.3): severe PAD or medial calcification; urgent vascular workup, no compression.
The ankle-brachial index is the ratio of the higher systolic blood pressure measured at the ankle (dorsalis pedis or posterior tibial) to the higher systolic pressure measured in either brachial artery. It is performed with a handheld continuous-wave Doppler and a standard blood pressure cuff, with the patient supine for at least 10 minutes. The measurement is non-invasive, requires no preparation, and can be completed in 10 minutes at the bedside. In patients with non-compressible vessels due to medial calcification—commonly diabetics and patients with end-stage renal disease—the toe-brachial index (TBI) is more reliable. A TBI below 0.7 indicates significant ischemia regardless of ABI value. Transcutaneous oxygen measurement (TcPO2) is an additional adjunct in difficult cases; values below 30 mmHg are associated with poor healing.
Venous ulcers result from sustained venous hypertension caused by failed valves in the superficial, perforating, or deep venous system. The elevated pressure transmits to the dermal capillary bed, causing fibrin cuffing, leukocyte trapping, growth factor sequestration, and chronic inflammation. The corrective treatment is to mechanically reduce venous pressure—primarily through external compression that supports the calf pump and reduces ambulatory venous pressure. Arterial ulcers, by contrast, result from inadequate inflow. The corrective treatment is to restore arterial flow through risk-factor modification and revascularization. Compression in this setting further reduces the already-inadequate perfusion and can precipitate gangrene. The two treatments are diametrically opposed; misapplication of one can be catastrophic.
The standard treatment for an uncomplicated venous leg ulcer involves multilayer compression, appropriate dressings, sharp debridement of slough at every visit, leg elevation, and ambulation to support the calf pump. The Cochrane systematic review on compression for venous leg ulcers shows that compression heals more wounds than no compression and that multilayer high-compression systems heal more wounds than single-layer or low-compression systems. Healing rates of 60% to 75% at 24 weeks are achievable with consistent multilayer compression in patients with adequate arterial inflow.
Compression is the foundation, but it does not address the underlying valve incompetence. The 2014 EVRA trial published in the New England Journal of Medicine demonstrated that early endovenous ablation of superficial reflux improved 24-week healing rates and reduced ulcer recurrence compared with compression alone. Modern superficial ablation techniques include radiofrequency ablation, endovenous laser ablation, mechanochemical ablation (ClariVein), and cyanoacrylate closure (VenaSeal). For deep venous obstruction, iliac vein stenting after intravascular ultrasound evaluation has emerged as a high-impact intervention for selected patients with persistent ulceration despite compression. Healix360-coordinated wound clinicians refer appropriate patients to vascular surgery and venous medicine partners for these interventions.
The standard treatment for an arterial ulcer requires that the underlying perfusion deficit be characterized and, when feasible, corrected. Wound care alone will not heal an arterial ulcer if inflow remains inadequate. The pathway begins with vascular imaging—most commonly arterial duplex ultrasound followed by CT angiography or formal catheter angiography—to define the level and severity of disease. Revascularization options include endovascular angioplasty, atherectomy, drug-coated balloons, and stenting; surgical bypass remains the standard for selected patients with adequate single-segment great saphenous vein, as supported by the BEST-CLI trial published in JAMA in 2022.
Mixed venous and arterial disease occurs in 10% to 20% of leg ulcers and complicates treatment. The clinical decision is whether modified compression can be applied safely. In general, an ABI between 0.5 and 0.8 may permit reduced compression at 23 to 30 mmHg using short-stretch bandages or specialized mixed-etiology systems with close monitoring. ABI below 0.5 contraindicates compression entirely until revascularization restores inflow. Toe pressures and TcPO2 add precision when ABI is borderline or non-compressible. These patients benefit most from coordinated mobile evaluation that brings vascular and wound expertise into the same conversation rather than fragmenting decisions across multiple appointments.
Venous ulcers occur in the gaiter region with hyperpigmentation, edema, moderate-heavy exudate, and palpable pulses; treatment is multilayer compression. Arterial ulcers occur on the toes, foot, or pretibial region with shiny atrophic skin, minimal exudate, and absent pulses; treatment is revascularization first, then careful wound care. Mixed-etiology ulcers require ABI-based decisions about modified compression and often need vascular intervention before aggressive wound management.
Approximately 10% of chronic leg ulcers are not venous, arterial, or mixed. The differential includes pyoderma gangrenosum, vasculitis (including granulomatosis with polyangiitis and microscopic polyangiitis), calciphylaxis, sickle cell ulcers, hydroxyurea-induced ulcers, malignancy (Marjolin's ulcer, basal cell carcinoma, squamous cell carcinoma), and infection (mycobacterial, fungal, syphilitic). Any leg ulcer that fails to progress with appropriate venous or arterial treatment for 12 weeks should prompt consideration of biopsy. Healix360-coordinated clinicians perform punch biopsies at the bedside when atypical features are present and coordinate dermatopathology and rheumatology consultation as indicated.
"Compression heals venous ulcers and harms arterial ulcers. The most important moment in chronic leg-wound care is the moment a clinician decides which it is. That decision should never be made without an ABI." — Healix360 Clinical Team
Cellular and tissue-based products (CTPs)—commonly called skin substitutes—have strong evidence in venous and diabetic foot ulcers when standard care has failed to reduce wound area by at least 50% in four weeks. The most studied options for venous ulcers include bilayered living cell constructs (Apligraf), human amniotic membrane allografts (EpiFix, Grafix, AmnioBand), and acellular dermal matrices (Oasis, Integra). Selection depends on wound depth, exudate level, periwound condition, and payer authorization criteria. CTPs are not a substitute for compression in venous ulcers; they are an adjunct that accelerates closure when compression alone has stalled. In arterial ulcers, CTPs should not be applied until perfusion is adequate to support graft take.
Patients with chronic leg ulcers are often elderly, have limited mobility, and find clinic visits exhausting. The diagnostic process—ABI measurement, vascular referral, biopsy, and weekly compression changes—can extend over months when fragmented across multiple outpatient visits. Healix360-coordinated mobile clinicians collapse these steps into bedside visits, performing ABI on the first visit, applying multilayer compression the same day when arterial inflow is confirmed adequate, and arranging vascular consultation when it is not. This integrated workflow shortens time-to-treatment, improves adherence, and produces healing outcomes comparable to or better than fragmented outpatient care.
Healix360-coordinated leg-ulcer differential evaluations are available across nine SoCal counties—LA, Orange, Riverside, San Bernardino, Ventura, Santa Barbara, Kern, San Luis Obispo, and San Diego—and the Las Vegas metro area in Clark and Nye counties, NV. Call 877-545-1300 to request bedside ABI and wound evaluation.
Some clues are visible to non-clinicians: venous ulcers usually appear in the lower leg around the inner ankle with surrounding brownish skin discoloration and swelling, while arterial ulcers typically appear on the toes or outer ankle with shiny, hairless skin and severe pain that improves when the leg is dangled. However, definitive classification requires an ankle-brachial index, which a clinician must perform. Do not apply compression at home without professional evaluation; doing so on an arterial ulcer can be dangerous.
The ABI is the single most important test for differentiating venous from arterial leg disease and for determining whether compression is safe. A normal ABI of 0.9 to 1.3 means arterial flow is adequate to support compression therapy. An ABI below 0.7 indicates significant peripheral arterial disease that requires vascular evaluation before any compression is applied. ABI testing is non-invasive, takes 10 minutes at the bedside, and is performed on every initial leg-ulcer evaluation in our coordinated pathway.
Yes. The Cochrane systematic review on compression for venous leg ulcers consistently shows that multilayer high-compression systems heal more wounds than single-layer or low-compression systems. Four-layer systems such as Profore and two-layer systems such as Coban 2 produce comparable outcomes, and selection often depends on patient comfort, leg shape, and clinician familiarity. The key factor is sustained ankle pressure of 30 to 40 mmHg, which single-layer wraps rarely achieve.
Compression on a leg with significant peripheral arterial disease further reduces already-inadequate blood flow and can precipitate ischemic pain, tissue necrosis, and limb loss. This is why the ABI must be established before compression is applied. If compression has been mistakenly applied and the patient develops new pain, color change, or worsening of the wound, the compression should be removed immediately and vascular evaluation arranged. This is a true emergency in the setting of severe PAD.
With consistent multilayer compression, appropriate dressings, and bedside debridement, 60% to 75% of venous leg ulcers heal within 24 weeks. Larger wounds, longer-duration wounds, and wounds with mixed etiology heal more slowly. Recurrence is common—40% to 70% within five years—unless underlying venous disease is treated with endovenous ablation and patients continue lifelong compression stocking use after wound closure.
The 2014 EVRA trial in the New England Journal of Medicine demonstrated that early endovenous ablation of superficial venous reflux improves 24-week healing rates and reduces recurrence compared with compression alone. Modern ablation techniques include radiofrequency ablation, endovenous laser ablation, mechanochemical ablation (ClariVein), and cyanoacrylate closure (VenaSeal). Patients with documented superficial reflux on duplex ultrasound should be evaluated for ablation as part of comprehensive venous ulcer treatment.
Most arterial ulcers will not heal without revascularization. The threshold is generally an ABI below 0.5, a toe pressure below 30 mmHg, or a TcPO2 below 30 mmHg in the presence of an open wound. Revascularization options include endovascular angioplasty, atherectomy, drug-coated balloons, stenting, and surgical bypass. The 2022 BEST-CLI trial helps guide the choice between endovascular and open surgical approaches based on conduit availability and patient comorbidity.
A mixed-etiology ulcer has features of both venous and arterial disease, typically with an ABI between 0.5 and 0.9. Treatment depends on the severity of arterial disease. Modified compression at 23 to 30 mmHg using short-stretch bandages may be acceptable when ABI is between 0.7 and 0.9, while ABI below 0.5 contraindicates compression entirely until revascularization restores inflow. These patients benefit most from coordinated wound and vascular evaluation rather than fragmented care.
Yes. Cellular and tissue-based products such as Apligraf, EpiFix, Grafix, Oasis, and Integra have strong evidence in venous leg ulcers when standard compression and dressing care have failed to reduce wound area by 50% within four weeks. Skin substitutes are an adjunct to compression, not a replacement. Medicare covers FDA-cleared skin substitutes for venous leg ulcers when documentation demonstrates failure of four weeks of optimized standard care.
Pyoderma gangrenosum, vasculitis (including granulomatosis with polyangiitis), calciphylaxis, malignancy (such as Marjolin's ulcer or squamous cell carcinoma), and infection (mycobacterial, fungal, or syphilitic) can all mimic venous or arterial ulcers. Any leg ulcer that fails to progress with 12 weeks of appropriate venous or arterial treatment should prompt consideration of punch biopsy. Atypical morphology, rapidly progressive borders, or systemic symptoms should prompt earlier biopsy and rheumatology consultation.
Yes, the great majority can. Bedside ABI, sharp debridement, multilayer compression application, advanced dressing care, and biologic application are all routinely delivered in the home. Vascular procedures and selected surgical interventions require outpatient or hospital settings, but patients return home for the bulk of recovery under coordinated mobile care. Healix360 coordinates the transitions between home, clinic, and vascular suite so patients are not lost in handoffs.
Yes. Professional services delivered by physicians and nurse practitioners are billed under Medicare Part B and are covered when medically necessary. Bedside ABI is covered as part of the evaluation. Compression supplies are covered under specific Part B conditions when applied by a clinician. FDA-cleared cellular and tissue-based products are covered for venous leg ulcers when documentation supports medical necessity. Standard 80/20 Part B cost sharing applies, and most supplemental plans cover the remainder.
Call 877-545-1300 or request a provider to begin care. Healix360 serves Southern California and Nevada and accepts Medicare Part B and most major insurance plans.